drugset / Trial / NCT05259696
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Timeline
- Start
- 2022-02-11
- Primary completion
- 2024-10-24
- Completion
- 2024-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | E-602 | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | E-602 | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | E-602 | Protein / enzyme biologic | 10 mg/kg | Intravenous |
| Subject | E-602 | Protein / enzyme biologic | 20 mg/kg | Intravenous |
| Subject | E-602 | Protein / enzyme biologic | 30 mg/kg | Intravenous |